Abstract
Background Depression is a highly prevalent and heterogenous disorder. This study aims to determine whether depression with atypical features shows different heritability and different degree of overlap with polygenic risk for psychiatric and immuno-metabolic traits than other depression subgroups.
Methods Data included 30,069 European ancestry individuals from the UK Biobank who met criteria for lifetime major depression. Participants reporting both weight gain and hypersomnia were classified as ↑WS depression (N = 1,854) and the others as non-↑WS depression (N = 28,215). Cases with non-↑WS depression were further classified as ↓WS depression (i.e. weight loss and insomnia; N = 10,142). Polygenic risk scores (PRS) for 22 traits were generated using genome-wide summary statistics (Bonferroni corrected p=2.1×10−4). Single nucleotide polymorphism (SNP)-based heritability of depression subgroups was estimated.
Results ↑WS depression had a higher polygenic risk for BMI (OR=1.20, [1.15-1.26], p=2.37e-14) and C-reactive protein (OR=1.11, [1.06-1.17], p=8.86e-06) vs. non-↑WS depression and ↑WS depression. Leptin PRS was close to the significance threshold (p=2.99e-04), but the effect disappeared when considering GWAS summary statistics of leptin adjusted for BMI. PRS for daily alcohol use was inversely associated with ↑WS depression (OR=0.88, [0.83-0.93], p=1.04e-05) vs. non-↑WS depression. SNP-based heritability was not significantly different between ↑WS depression and ↓WS depression (14.3% and 12.2%, respectively).
Conclusions ↑WS depression shows evidence of distinct genetic predisposition to immune-metabolic traits and alcohol consumption. These genetic signals suggest that biological targets including immune-cardiometabolic pathways may be relevant to therapies in individuals with ↑WS depression.
Competing Interest Statement
Cathryn Lewis is a member of the Scientific Advisory Board of Myriad Neurosciences. Matthew Hotopf is principal investigator of RADAR-CNS (funded by European Commission, Janssen, Biogen, UCB, MSD and Lundbeck).
Funding Statement
This research was supported by the UK Medical Research Council (MR/N015746 and MR/S0151132). This paper represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Chiara Fabbri is supported by Fondazione Umberto Veronesi (https://www.fondazioneveronesi.it).
The authors acknowledge use of the research computing facility at King’s College London, Rosalind (https://rosalind.kcl.ac.uk), which is delivered in partnership with the National Institute for Health Research (NIHR) Biomedical Research Centres at South London & Maudsley and Guy’s & St. Thomas’ NHS Foundation Trusts, and part-funded by capital equipment grants from the Maudsley Charity (award 980) and Guy’s & St. Thomas’ Charity (TR130505).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
UK Biobank data was accessed under application 18177.
